15:55 uur 12-12-2018

Altasciences draagt bij aan positieve Top-Line Fase 1 resultaten voor chronisch hoestmiddel-kandidaat

LAVAL, Quebec –(BUSINESS WIRE)– Altasciences voltooide onlangs een belangrijke First-in-Human (FIH), Fase I, geïntegreerde adaptieve klinische studie, met inbegrip van enkele en meervoudige oplopende doses (SAD en MAD), Project Management, Bio-analyse en medisch schrijven, voor sponsor Bellus Health.

Altasciences ‘bijdragen aan de positieve top-line resultaten waren significant. Van de werving van 90 proefpersonen tot het beheer van alle relevante aspecten van deze belangrijke FIH-proef, heeft Altasciences gebruik gemaakt van een flexibele en adaptieve aanpak om volledig aan de behoeften van de klant te voldoen. Dankzij de bijdragen van Altasciences kon Bellus Health een goed geïnformeerde beslissing nemen om door te gaan met hun veelbelovende kandidaat-geneesmiddel voor chronische hoest.

Altasciences Contributes to Positive Top-Line Phase 1 Results for Chronic Cough Drug Candidate

LAVAL, Quebec–(BUSINESS WIRE)– Altasciences recently completed an important First-in-Human (FIH), Phase I, integrated adaptive clinical trial, including single and multiple ascending doses (SAD and MAD), Project Management, Bioanalysis, and Medical Writing, for sponsor Bellus Health.

Altasciences’ contributions to the positive top-line results were significant. From recruitment of 90 subjects to management of all relevant aspects of this important FIH trial, Altasciences used a flexible and adaptive approach to fully meet the client’s needs. Altasciences’ contributions allowed Bellus Health to make a well-informed decision to proceed with their promising drug candidate for chronic cough.

We awarded this trial to Altasciences based on their reputation for quality, speed and efficiency, and we were not disappointed. Thanks to their great efforts, we have been able to determine that our compound is safe and well-tolerated, and we are proceeding to the next stage of development without delay. Altasciences’ ability to deliver results efficiently helped us make important decisions to move ahead,” says Dr. Denis Garceau, Senior Vice President, Drug Development, at Bellus Health.

Altasciences conducts hundreds of early phase clinical trials annually. Their vast participant database permits rapid recruitment, and they are constantly refining their processes and offerings to better meet sponsor needs.

We are very proud of our work on novel compounds at Altasciences, and the fact that we’re able to deliver results in a timely, efficient manner that meets or exceeds our sponsors’ drug development timelines,” says Ingrid Holmes, Vice President, Global Clinical Operations, for Altasciences.

About Altasciences

Altasciences is a mid-size contract research organization with a unique focus on supporting drug development from lead candidate selection to proof of concept. Altasciences encompasses Algorithme Pharma in Montreal, QC, Vince & Associates Clinical Research in Kansas City, KS, Algorithme Pharma USA in Fargo, ND, and Altasciences Preclinical Services in Seattle, WA. With over 25 years of industry experience, Altasciences provides preclinical and clinical solutions to an international customer base of biopharmaceutical companies. Altasciences’ full-service solutions offering in this critical stage of drug development includes preclinical safety testing, clinical pharmacology services, bioanalysis, medical writing, biostatistics, data management, and overall program management.

Contacts

Julie-Ann Cabana
jcabana@altasciences.com
913 304-4505

Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, die als enige rechtsgeldig is. Check out our twitter: @NewsNovumpr